On July 29, 2025, MIRA Pharmaceuticals announced preclinical results showing that their new topical Ketamir-2 formulation effectively reduces both acute and inflammatory pain, comparable to injected morphine. The study indicates potential for Ketamir-2 as a non-opioid treatment for various pain conditions.